抗PLA2R抗体在膜性肾病中的应用:发现十年后的已知与未知
2009年发现M型磷脂酶A2受体(PLA2R)为膜性肾病(MN)主要靶抗原,推动基础与临床研究。原发性MN现被视为肾脏局限性自身免疫病,不同种族患者中抗PLA2R抗体(aPLA2Rab)检出率为70-80%。aPLA2Rab作为诊断和预后生物标志物已被广泛接受,但自身免疫应答发生、IgG亚类与抗原表位作用及足细胞损伤通路等问题仍未解决。
要点
- aPLA2Rab在原发性MN患者中检出率为70-80%,支持其作为诊断标志物。
- PLA2R相关MN可能由遗传易感、免疫耐受丧失、抗原表达改变及环境因素共同驱动。
- IgG亚类、抗原表位及补体协同致病机制尚待阐明,以优化靶向治疗。
核心结论
- aPLA2Rab是原发性MN诊断和预后的生物标志物,但抗体形成机制和致病通路仍待明确。
研究设计与样本
- 综述,总结PLA2R发现十年后关于aPLA2Rab在膜性肾病中的已知与未解问题。
主要发现
- 原发性MN被视为肾脏局限性自身免疫病,不同种族患者aPLA2Rab检出率为70-80%。
- PLA2R相关MN可能受遗传易感性、免疫耐受丧失、抗原表达改变及空气污染、吸烟、感染等环境因素影响。
- IgG亚类、抗原表位及补体协同在足细胞损伤和蛋白尿产生中的作用尚未完全阐明。
临床怎么用
- aPLA2Rab可用于原发性MN的诊断和预后评估。
- 需进一步研究遗传因素、B/T细胞表位及足细胞损伤机制以识别进展风险患者并开发靶向治疗。
局限性
- 综述未提供原始研究数据,部分机制问题仍无明确结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The discovery in 2009 of the M-type phospholipase A2 receptor (PLA2R) as the primary target in membranous nephropathy (MN) greatly advanced basic and clinical research. Primary MN is now considered a renal-limited autoimmune disease, with antibodies against PLA2R (aPLA2Rab) identified in 70-80 % of patients of various ethnic groups. Although the use of aPLA2Rab as a diagnostic and prognostic biomarker is now widely accepted, many questions related to the development of the auto-immune response, the role of IgG subclasses and antigenic epitopes, and the pathways to podocyte injury remain unresolved. PLA2R-associated MN most likely develops governed by factors such as genetic susceptibility, loss of tolerance, alterations in antigen expression with a role for environmental factors like air pollution, smoking, and infections. More detailed knowledge of genetic factors, the relevant B- and T-cell epitopes, and the mechanisms of podocyte injury is needed to identify patients at risk for disease progression and to develop optimized, targeted treatment strategies. In this review we highlight unresolved issues, addressing initiation of antibody formation, the timeline of antibody production, the role of IgG subclass, and the pathogenicity of the antibodies in concert with complement to produce glomerular pathology and proteinuria.
引用
- van de Logt AE, Fresquet M, Wetzels JF, et al. The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery. Kidney Int. 2019. PMID: 31611068. doi:10.1016/j.kint.2019.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。